Aladdin Healthcare Technologies will obtain an equity stake in public spinoff No-Age Biotech Inc. at TSX, aimed to combat age-related diseases
- Aladdin has agreed to obtain a 25% equity stake in No-Age Biotech Inc., publicly traded spinoff at TSX, in late 2020.
- No-Age Biotech will be focused on the development of therapeutics to combat age-related diseases.
- Aladdin plans to develop a bespoke drug discovery platform to be contributed to No-Age Biotech in exchange for its stake.
- No-Age Biotech will be targeting an initial valuation of $50 - $75 million or their Series A investment round.
BERLIN/LONDON, September 24, 2020 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has agreed to obtain an equity stake in a spin-off company at the TSX (Toronto Stock Exchange) in late 2020. The spinoff has just been established and will be named No-Age Biotech Inc. The deal is subject to final terms that will be agreed in October this year. Aladdin will inform the capital market about the agreement with a further press release at an appropriate time.
Among the other founding shareholders, there are renowned and experienced professionals in the field of age-related diseases: Professor David Rubinsztein, Fellowship of the Academy of Medical Sciences and Fellow of the Royal Society, who is the Deputy Director of Cambridge Institute for Medical Research, University of Cambridge; NO-Age, a Norwegian integrated, interdisciplinary, center for human ageing research at international top level.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: “Aladdin plans to develop a bespoke drug discovery platform which we intend to contribute to No-Age Biotech in exchange for the 25% stake. We also expect to become the exclusive AI provider to No-Age Biotech and generate an annual fee for both development and management of the AI platform, therefore bringing significant potential value to Aladdin.”
Aladdin has already achieved milestones in drug development against Alzheimer’s and other age-related diseases, marking a new era for a faster and optimized identification of drug targets. In May this year, the Company announced the development of new mitophagy inducers through a novel system for virtual drug screening based on Artificial Intelligence, which is actually a key component of Aladdin’s drug development platform (AIDD). This new agreement confirms again Aladdin’s capability to play a relevant role in the worldwide scientific progress with its self-developed AI Drug Discovery platform AIDD and to improve the health conditions of patients with age-related and neurodegenerative diseases.
About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.
Website Link: www.aladdinid.com
TICKER SYMBOL: NMI
For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
CROSS ALLIANCE communication GmbH
Phone +49 89 1250 90330